As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...

Earlier, systematic supportive and palliative integration, plus streamlined logistics and clearer counseling on novel-therapy AE profiles, could reduce household disruption during treatment and ...

Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity. 259 Prospect Plains Rd, Bldg H Cranbury, NJ ...

Since sickle cell disease trial criteria exclude most patients, Julie Kanter, MD, advocated for broader end points and real-world monitoring to improve inclusion. Current sickle cell disease (SCD) ...

Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

Regulatory labeling stratifies use by PD-L1 status: monotherapy for PD-L1–negative/checkpoint-ineligible disease and combination with pembrolizumab (or Qlex) for PD ...

In this episode, 'Epcoritamab in RRFL: Efficacy Data, Administration Considerations, and the Pharmacist's Operational Role,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions: In ...

In 'From Promise to Practice: Overcoming Access and Administration Challenges for Bispecifics in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical question: In 'From ...

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...